CAJ | 학술논문

目的：分析比较紫杉醇脂质体和多西紫杉醇在乳腺癌新辅助化疗中的应用效果及安全性。方法回顾性分析188例接受新辅助化疗的可手术乳腺癌患者，根据不同用药情况分为紫杉醇脂质体组（86例）和多西紫杉醇组（102例），两组患者均联合表阿霉素和环磷酰胺，即三药联合方案新辅助化疗，每21 d为1个周期，共6个周期，化疗结束后3周行手术治疗，对其化疗效果及不良反应进行分析。结果紫杉醇脂质体组和多西紫杉醇组患者的病理完全缓解率分别为10．5％（9／86）和9．8％（10／102），客观缓解率分别为80．2％（69／86）和79．4％（81／102），疾病控制率分别为95．3％（82／86）和93．1％（95／102），但差异无统计学意义（P＞0．05）。安全性分析显示，紫杉醇脂质体组的皮肤指甲毒性反应、体液潴留、口腔黏膜炎、过敏反应（包括颜面潮红、胸闷、心悸、呼吸困难等）、Ⅲ～Ⅳ级白细胞减少及中性粒细胞减少的发生率均低于多西紫杉醇组，差异均有统计学意义（均P＜0．05）。结论紫杉醇脂质体的抗肿瘤疗效与多西紫杉醇相近，但不良反应较少，且程度较轻，安全性更高。
목적：분석비교자삼순지질체화다서자삼순재유선암신보조화료중적응용효과급안전성。방법회고성분석188례접수신보조화료적가수술유선암환자，근거불동용약정황분위자삼순지질체조（86례）화다서자삼순조（102례），량조환자균연합표아매소화배린선알，즉삼약연합방안신보조화료，매21 d위1개주기，공6개주기，화료결속후3주행수술치료，대기화료효과급불량반응진행분석。결과자삼순지질체조화다서자삼순조환자적병리완전완해솔분별위10．5％（9／86）화9．8％（10／102），객관완해솔분별위80．2％（69／86）화79．4％（81／102），질병공제솔분별위95．3％（82／86）화93．1％（95／102），단차이무통계학의의（P＞0．05）。안전성분석현시，자삼순지질체조적피부지갑독성반응、체액저류、구강점막염、과민반응（포괄안면조홍、흉민、심계、호흡곤난등）、Ⅲ～Ⅳ급백세포감소급중성립세포감소적발생솔균저우다서자삼순조，차이균유통계학의의（균P＜0．05）。결론자삼순지질체적항종류료효여다서자삼순상근，단불량반응교소，차정도교경，안전성경고。
[Abts ract] Objective The aim of this study was to analyze the efficacy and safety of paclitaxel liposomal and docetaxel for neoadjuvant chemotherapy of breast cancer.Metho ds We retrospectively analyzed the clinical data of 188 operable patients with breast cancer who received neoadjuvant chemotherapy.According to the treatment regimens, they were divided into the group of paclitaxel liposome (86 patients) and group of docetaxel (102 patients) treatment.All the patients received a combination therapy with epirubicin and cyclophosphamide, i.e.neoadjuvant chemotherapy with three drugs, 21 days as a cycle, and a total of 6 cycles.Surgery was carried out three weeks after the end of chemotherapy, and the chemotherapy efficacy and adverse reaction of both groups were evaluated.Results Pathological complete response ( pCR ) rate in the paclitaxel liposome group and docetaxel group was 10.5% and 9.8%, respectively, the objective response rate ( ORR ) was 80.2% and 79.4%, respectively, and the disease control rate ( DCR) was 95.3%and 93.1%, respectively, showing a non-significant difference in therapy efficacy between the two groups ( P>0 .05) .Safety analysis indicated that all the occurrence rates of skin and nail toxic reaction, body fluid retention, oral mucositis, allergic reaction ( such as facial blushing, chest distress, palpitation, dyspnea.etc.), and gradeⅢ-Ⅳleukopenia and neutropenia in the paclitaxel liposome group were significantly lower than that of the docetaxel group ( all P<0.05) .Conclusions Compared with docetaxel, paclitaxel liposome has the same anti-tumor efficacy, but causes fewer and milder adverse reactions with a higher safety in the neoadjuvant chemotherapy for breast cancer.